gimsilumab

Ligand id: 9624

Name: gimsilumab

Classification
Compound class Antibody
International Nonproprietary Names
INN number INN
10534 gimsilumab
Synonyms
MORAb-022
Comments
Gimsilumab (MORAb-022) is an investigational, fully human IgG1 monoclonal antibody being evaluated for its potential in the treatment of multiple inflammatory diseases and cancer. It targets granulocyte-macrophage colony stimulating factor (GM-CSF, CSF2), a growth factor involved in autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis and asthma. In the cancer setting, MORAb-022-mediated blocking of CSF2 produces a pro-immunity microenvironment that leads to tumour tissue death in preclinical studies. Peptide sequences (from the WHO INN submission for gimsilumab) match sequences 8 and 12 from Morphotek Inc. patent WO2007092939 [1], and these sequences belong to monoclonal antibody clone G9 specified in the patent.
Database Links
Specialist databases
IMGT/mAb-DB 756
Other databases
GtoPdb PubChem SID 340590254
Search PubMed clinical trials gimsilumab
Search PubMed titles gimsilumab
Search PubMed titles/abstracts gimsilumab